Strategic Cooperation | Becoming a leading supplier and service provider of single-use bioprocessing systems

2022-04-19Company Events

JYSS BIO has always strategically aimed to achieve the goal of “becoming a leading supplier and service provider of single-use bioprocessing systems”, serving the biopharmaceutical companies with high-quality single-use technology and solution.

Recently, JYSS BIO actively expanded wide cooperation with leading biopharma companies, especially in the gene and cell therapy field. Since 2020, in the field of vaccines, JYSS has successfully delivered orders of single-use bioprocessing  equipment and consumables required for the production of COVID-19 vaccines for CanSino Biologics and Sinovac Biopharm. Meanwhile, the strategic cooperation with the 2 companies has been reached, and JYSS BIO will continue to be the core supplier to contribute to vaccine production. In the field of cell and gene therapy, JYSS BIO cooperates with the leading domestic CDMO company-OBiO, focus on gene therapy virus vector, to reach a strategic cooperation aiming to jointly promoting the localization of gene drugs and gene therapy. In the near future, JYSS BIO has also reached strategic cooperation with Huadao Biotechnology, a high-tech biopharmaceutical company specializing in cell immunotherapy, to provide a solid backing for the new progress of domestic innovative cell therapy.

CanSino Biologics is a leading high-tech biological product company in China. In 2021, the COVID-19 vaccine developed by CanSino Biologics has been approved by NMPA as the first adenovirus vector vaccine against COVID-19 in China. At present, the company has established five core technology platforms based on viral vector technology, synthetic vaccine technology, protein structure design and recombination technology, mRNA technology and preparation and drug delivery technology, and has a number of core intellectual property rights and proprietary technologies for vaccines.

Sinovac Biopharm is a leading company in developing recombinant protein drugs in China, and the first approved company with accomplished domestic recombinant protein vaccine of COVID-19 on R&D and production in China. By the end of 2021, Sinovac's vaccines have obtained emergency use approvals or conditional market authorization from 56 countries and regions. By last year, Sinovac had provided more than 2.5 billion doses of vaccines worldwide, and the company's current annual production capacity of Covid-19 vaccines has reached 2 billion doses. The vaccine of Sinovation is the most widely supplied and used COVID-19 vaccine in the world and in China, and it is also the largest exported Chinese COVID-19 vaccine.

OBiO is a biotechnology company focusing on the field of gene therapy, and  providing CRO services such as gene therapy vector development and gene function research for the basic research of gene therapy. It also provides IND-CMC pharmaceutical research and clinical samples for the research and development of gene drugs, CDMO services such as GMP production. As known, Gene therapy and cell therapy has broad prospects, with its listing on the Science and Technology Innovation Board in March 2022 , OBio has become the first stock of gene therapy company in China.

Huadao Biotech is a high-tech biopharmaceutical company specializing in cellular immunotherapy. The company has so far completed nearly 30 cases of CD19-CAR-T in the treatment of acute lymphoblastic leukemia and non-Hodgkin's lymphoma. It has also carried out the construction and preclinical cytology research of CAR vectors for a number of other tumors, such as AML (myeloid leukemia), MM (multiple myeloma), gastric cancer, liver cancer, pancreatic cancer, and glioma.

In future, JYSS BIO will fully take advancing the domestic biotechnology development as its own responsibility, providing its excellent team and high-quality products and services to help more biopharmaceutical companies to innovate their drug R&D pipelines.




Contact Us